Transarterial radioembolization with Yttrium-90 for regional management of hepatocellular cancer: The early results of a nontransplant center

Alicia Holt, Lawrence D. Wagman, Maheswari Senthil, Shaun McKenzie, Howard Marx, Yi Jen Chen, Nayana Vora, Joseph Kim

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Abstract

Selective arterial radioembolization with Yttrium-90 (Y-90) microspheres has shown promise for regional management of hepatocellular cancer (HCC). Our objective was to report our early experience with this treatment modality from a nontransplant center. Treatment of patients with HCC was discussed in a multidisciplinary tumor board. Patients with unresectable disease resulting from high lesion number, ill location of the tumor, poor hepatic reserve, or medical comorbidities were offered Y-90 treatment. Liver treatment was either lobar or tumor-targeted. Response to therapy was assessed by CT scan obtained within 3 months using Response Evaluation Criteria in Solid Tumors criteria. During 2007 to 2009, 40 Y-90 radioembolizations were performed in 20 patients with age that ranged from 16 to 87 years; four patients were 80 years old or older. After the first therapy, CT assessment of the treated area showed stable disease (n = 15), partial response (n = 3), and progression (n = 2). Of the two patients who progressed, one was retreated with a subsequent complete response. The other patient died of progressive disease. The most common side effects were mild fatigue, anorexia, and nausea. In summary, our nontransplant center experience shows that Y-90 radioembolization is a well-tolerated treatment in select patients with unresectable HCC with an associated high rate of local tumor control.

Original languageEnglish
Pages (from-to)1079-1083
Number of pages5
JournalAmerican Surgeon
Volume76
Issue number10
StatePublished - Oct 2010

ASJC Scopus subject areas

  • Surgery

Fingerprint

Dive into the research topics of 'Transarterial radioembolization with Yttrium-90 for regional management of hepatocellular cancer: The early results of a nontransplant center'. Together they form a unique fingerprint.

Cite this